Publication | Closed Access

Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer

Phase Ii EvaluationOncologyMedicineGynecologyCamptothecin AnalogPharmacotherapy-Resistant Ovarian CancerAnti-cancer AgentCancer TreatmentPharmacologyGynecology OncologyEndocrine-related CancerOvarian Cancer